Patent application number | Description | Published |
20120178908 | TARGETING TISSUE FACTOR TO ACTIVATED PLATELETS - The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with fusions proteins of the current invention. | 07-12-2012 |
20130142804 | Antibodies That Are Capable of Specifically Binding Tissue Factor Pathway Inhibitor - The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralising free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent. | 06-06-2013 |
20130251721 | Antibodies Against Tissue Factor Pathway Inhibitor - The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy. | 09-26-2013 |
20130251722 | Antibodies Against Tissue Factor Pathway Inhibitor - The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy. | 09-26-2013 |
20130253173 | Antibodies That Are Capable of Specifically Binding Tissue Factor Pathway Inhibitor - The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralising free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent. | 09-26-2013 |
20130266576 | THERAPEUTIC FACTOR VIII ANTIBODIES - The present invention relates to therapeutic FVIII antibodies. In particular, the present invention relates to FVIII antibodies having the ability to prolong the circulatory half life of FVIII. The present invention furthermore relates to use of such antibodies in treatment and prophylaxis of haemophilia A. | 10-10-2013 |
20130337537 | COAGULATION FACTOR-TARGETING TO TLT-1 ON ACTIVATED PLATELETS - The current invention relates to: procoagulant proteins which may, for example, be fusion proteins or chemical conjugates; methods of producing said procoagulant proteins; polynucleotides that encode said fusion proteins and cells that expresses them. Furthermore, the current invention relates to procoagulant proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with the procoagulant proteins of the current invention. | 12-19-2013 |
20130344090 | Antibodies Against Tissue Factor Pathway Inhibitor (TFPI) - The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce clotting time in (a) human FVIII-deficient plasma and/or (b) human whole blood. Such antibodies have utility in the treatment of bleeding disorders and in the stimulation of blood clotting. | 12-26-2013 |